ST. LOUIS, March 05, 2025--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the ...
SAN FRANCISCO--(BUSINESS WIRE)--Cofactor Genomics, developer of a leading platform for RNA sequencing and expression analysis, today announced $18M in financing led by Menlo Ventures with major ...
ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Cofactor AI, a company that helps hospitals appeal claims denials, announced it raised $4 million in a seed funding round led by Drive Capital. Cofactor AI’s platform, Cofactor Denial Suite, combines ...
As part of Y Combinator’s push into computational biology and bioinformatics, the early-stage firm is backing a team that used to work on the Human Genome Project and is now experimenting with RNA ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Cofactor AI has created software that uses artificial ...
San Francisco, California--(Newsfile Corp. - September 8, 2022) - Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT (Predicting Immunotherapy ...
Patent Represents Major Step Towards Bridging the Precision Medicine Gap Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right ...
PREDAPT Trial Validates RNA-Based Predictive Biomarker Across 1400+ Patients to Inform Immunotherapy Treatment in NSCLC Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results